|
|
Göran Wessman (1948)
Board member and Chairman since 2011.
Education: Biomedicine and Chemistry at Uppsala and Gothenburg Universities
Primary Experience: Leading positions at Nobel Pharma, consultant within business development. Founder of Protem Wessman Boule Diagnostics and Carmel Pharma. Former CEO of the holding company at Gothenburg University, A+ Science Holding and as Chairman of the Board of SCRI and Isconova.
Other assignments: CEO and board member in Mintage Scientific. Chairman in I-Tech, Vicore Pharma and Protem Wessman.
Number of shares: 512 500
Number of warrants: 0 |
| |
Per Bengtsson (1954)
Board member since 2011, President and CEO
Education: M.D, Ph.D. (cell biology)
Primary Experience: CEO of Probi AB (publ), R&D Manager Pharmacia/Pharmiacia&Upjohn PlasmaProducts, Medical Manager at Ferring and Development Manager at Bionor Immuno A/S.
Other assignments: Board member in Pharmavizer AB.
Number of shares: 0
Number of warrants: 0 |
| |
Christer Fåhraeus (1965)
Board member since 2011
Education: M.Sc. Bioengineering, B.Sc. Mathematics, Ph.D. (hc) Lund University. 3 years of medical studies and 4 years of of PhD studies in Neurophysiology.
Primary Experience: Innovator and Entrepreneur. CEO and Board member in several developmental companies and listed companies within medtech, IT and pharmaceuticals. Founder of Anoto Group AB, Precise Biometrics AB, CellaVision AB, Respiratorius AB, Agellis Group AB and EQL Pharma AB amongst others.
Other assignments: CEO of EQL Pharma AB. Chairman of Agellis Group AB, Respiratorius AB and Flatfrog Laboratories AB. Board member of EQL Pharma AB, Lunds University’s Utvecklingsaktiebolag (LUAB), Fårö Capital AB and CellaVision AB.
Number of shares: 0
Number of warrants: 0 |
| |
Elisabeth Lindner (1956)
Board member since 2011
Education: M.Sc., MBA.
Primary Experience: Senior management positions in the pharmaceutical industry, including CEO of Diamyd Medical AB, Director of Biopharma Process Development at Octapharma AB, Director of development Metcon Medicin AB, Senior Director Global New Product Introduction Pharmacia Corporation, among others.
Other assignments: Chairman and CEO in Biosource Europe AB. Board member in BioInvent International AB, IND Technologies, member of The Royal Swedish Academy of Engineering Sciences (IVA).
Number of shares: 0
Number of warrants: 0 |
| |
Jan N. Sandström (1938)
Board member since 2011
Education: Pharmacist, university studies in economy.
Primary experience: International marketing, global project management, , commercialization and business development within AstraZeneca and as vice president Business Development and Licensing in one of the research companies at AstraZeneca. Consultant specializing in strategy, global business development and recruitment.
Other assignments: Board member in Accelerator AB, GrippingHeart AB, NovaSAID AB, PledPharma AB, TikoMed AB and chairman in JNS.
Number of shares: 0
Number of warrants: 0 |
| |
Anders Waas (1957)
Board member since 2011
Education: Dentist
Primary Experience: CEO in pharmaceutical-, medical device and biotech companies and senior positions in product development, business development and commercialization at AstraZeneca, Ciba Geigy, WL GORE &Associates, CV Therapeutics, and Actogenics.
Other assignments: MIVAC Development AB, Anders Waas AB and Juristfirma Louise Katsler Waas AB.
Number of shares: 0
Number of warrants: 0 |
| |
Bo Carlsson (1958)
Employee representative since 1997.
Education: Specialist teacher exam, Uppsala University
Primary experience: Employed by Karo Bio since 1997, Project Manager
Number of shares: 20 666
Number of warrants: 0 |
| |
Johnny Sandberg (1967)
Employee representative since 2006.
Education: Biomedical analyst, Vårdhögskolan.
Primary experience: Employed by Karo Bio since 2006, Senior Research Investigator
Number of shares: 26 500
Number of warrants: 0 |
| |
Eva Koch (1966)
Employee representative (Deputy Board member) since 2010.
Education: PhD. in organic chemistry.
Primary experience: Employed by Karo Bio since 1999, Senior Research Scientist
Number of shares: 6 500
Number of warrants: 0 |
